Methods of treatment by administering an anti-BCMA antibody

Details Methods of treatment by administering an anti-BCMA antibody Methods of treatment by administering an anti-BCMA antibody

2006-08-01

2006-08-01

Kemmerer, Elizabeth (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S141100, C424S143100, C424S173100, C530S387100, C530S387300, C530S388220, C514S012200

Reexamination Certificate

active

07083785

ABSTRACT:
A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

REFERENCES:
patent: 5969102 (1999-10-01), Bram et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6316222 (2001-11-01), Bram et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6475987 (2002-11-01), Shu
patent: 6541224 (2003-04-01), Yu et al.
patent: 6774106 (2004-08-01), Theill et al.
patent: 6869605 (2005-03-01), Browning et al.
patent: 2002/0037852 (2002-03-01), Browning et al.
patent: 2002/0172674 (2002-11-01), Jeffrey et al.
patent: 2003/0023038 (2003-01-01), Rennert et al.
patent: 2003/0082175 (2003-05-01), Schneider et al.
patent: 2004/0013674 (2004-01-01), Ambrose et al.
patent: 2004/0072188 (2004-04-01), Ambrose et al.
patent: 0 869 180 (1998-10-01), None
patent: WO 97/33902 (1997-09-01), None
patent: WO 98/18921 (1998-05-01), None
patent: WO 98/27114 (1998-06-01), None
patent: WO 98/55620 (1998-12-01), None
patent: WO 98/55621 (1998-12-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/12964 (1999-03-01), None
patent: WO 99/12965 (1999-03-01), None
patent: WO 99/33980 (1999-07-01), None
patent: WO 00/26244 (2000-05-01), None
patent: WO 00/39295 (2000-07-01), None
patent: WO 00/40716 (2000-07-01), None
patent: WO 00/43032 (2000-07-01), None
patent: WO 00/50633 (2000-08-01), None
patent: WO 00/58362 (2000-10-01), None
patent: WO/ 0068378 (2000-11-01), None
patent: WO 01/24811 (2001-04-01), None
patent: WO 02/02641 (2002-01-01), None
patent: WO 02/18620 (2002-03-01), None
patent: WO 03/055979 (2003-07-01), None
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29(37): 8509-8517, 1990.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Moore, G. Genetically engineered antibodies. Clin Chem 35(9): 1849-1853, 1989.
Ballow et al. Immunopharmacology, Immunomodulation and Immunotherapy. J Am Med Assoc 278(22: 2008-2017, 1997.
Daniel et al. Virology 202:540-549, 1994.
Elgert, K. Immunology, understanding the immune system. New York: Wiley-Liss, Inc., 1996, pp. 305, 324-326.
Colcher et al. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 43: 132-139, 1999.
Do et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192(7): 953-964, 2000.
MacKay et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 190(11):1697-1710, 1999.
Moore et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 285(5425):260-263, 1999.
Rennert et al. A soluble form of B cell maturation antigen a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 192(11):1677-1683, 2000.
Thompson et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 293(5537):2108-2111, 2001.
Wu et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem. 275(45):35478-35485, 2000.
Yan et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol. 1(1):37-41, 2000.
Yu et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 1(3):252-256, 2000.
Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol. 28(11):1171-1181, 1991.
Li et al. beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities. Proc Natl Acad Sci U S A. 77(6):3211-3214, 1980.
Gras et al., “BCMAp: an Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes”. International Immunology, vol. 7, No. 7, 1995, pp. 1093-1106.
Gross et al., “TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease”, Nature, vol. 404, Apr. 27, 2000, pp. 995-999.
Kwon et al., “Functions of Newly Identified Members of the Tumor Necrosis Factor Receptor Ligand Superfamiies in Lymphocytes”. Current Opinion in Immunology. 1999, pp. 340-345.
Laabi et al., “A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4; 16)(q26;p13) Translocation in a Malignant T Cell Lymphoma”. The EMBO Journal. vol. 11 No. 11, 1992. pp. 3897-3904.
Laabi et al., “The BCMA Gene. Preferentially expressed during B Lymphonal Maturation. is Bidirectionally Transcribed”. Nucleic Acids Research. vol. 22 No. 7, 1994, pp. 1147-1154.
Maldry et al., “The Characterization of Murine BCMA Gene Defines it as a New Member of the Tumor Necrosis Factor Receptor Superfamily”. International Immunology. vol. 10,No. 11, 1998. pp. 1698-1702.
Pitti et al., “Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer”. Nature. vol. 396. Dec. 17, 1998, pp. 699-703.
Schneider et al., “BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth”, J. Exp. Med., vol. 189, No. 11, Jun. 7, 1999, pp. 1747-1756.
Thompson et al., “BAFF Interacts with the Orphan Receptor, BCMA”. Scandinavian Journal of Immunology. vol. 51 (supplement 1), 2000, p. 65.
Thompson et al., “BAFF Binds to the Tumor Necrosis Factor Receptor like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population”, J. Exp. Med., vol. 192, No. 1, Jul. 3, 2000, pp. 129-135.
Hahne et al., “APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth,”J. Exp. Med. 188:1185-1190 (1998).
Kashii, Y. et al., “Constitutive Expression and Role of the TNF Family Ligands in Apoptotic Killing of Tumor Cells By Human NK Cells,”J. Immunol. 163:5358-66 (1999).
von Bülow & Bram, “NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily,”Science278:138-141 (1997).
Ward, P. and Mulligan, M. “Blocking of Adhesion Moleculesin vivoAs Anti-Imflammatory Therapy,”Ther. Immunol. 1:165-71 (1994).
Ware, C., “APRIL and BAFF Connect Autoimmunity and Cancer,”J. Exp. Med. 192:F35-F37 (2000).
Xia et al., “TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation,”J. Exp. Med. 192:137-143 (2000).

Affiliated with

Also associated with

Rating

Methods of treatment by administering an anti-BCMA antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treatment by administering an anti-BCMA antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment by administering an anti-BCMA antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3646679